| Catalog No. | AB941014 |
|---|
| Applications | ELISA |
|---|
| Host species | Rabbit |
|---|
| Isotype | IgG |
|---|
| Clonality | Polyclonal |
|---|
| Immunogen | Ranibizumab |
|---|
| Target | Rabbit polyclonal to Lucentis. |
|---|
| Specificity | The product is specific for Ranibizumab. This antibody serves as an excellent positive control for Ranibizumab immunogenicity (ADA) assays. |
|---|
| Purification | Purified by antigen affinity column. |
|---|
| Accession | 347396-82-1 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300. |
|---|
| Product Usage Information |
| Application |
Dilution |
| ELISA |
1:5000-1:20000 |
| IHC |
1:50-1:500 |
| WB |
1:500-1:2000 |
|
|---|
| Stability and Storage | The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles. |
|---|
| Background | Ranibizumab with trade name Lucentis, is an FDA-approved drug for the treatment of patients with neovascular (Wet) age-related macular degeneration (AMD) and macular edema following retinal vein occlusion (RVO). It is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment. Ranibizumab binds to vascular endothelial growth factor A (VEGF-A) and blocks its activity. Antibodysystem Anti-Ranibizumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Ranibizumab.
|
|---|
| Note | For research use only. |
|---|
